Leukemia Therapeutics Market: Robust Growth Expected with Innovative CAR-T Treatments
January 23, 2024 15:23 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023 09:15 ET
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Global Leukemia Therapeutics Market Report 2023: Rising Prevalence of Leukemia is Driving Growth
May 08, 2023 05:33 ET
|
Research and Markets
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Leukemia Therapeutics Global Market Report 2023: Rises in Product Approvals and Increasing Diagnosis Awareness Drives Growth
May 02, 2023 07:33 ET
|
Research and Markets
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Market by Type, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been...
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
April 12, 2022 07:00 ET
|
Cyclacel
-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS,...
Acute Myeloid Leukemia (AML) Market Insights & Epidemiology Analysis & Forecasts, 2018-2020 & 2021-2030: Major Markets, Marketed Therapies, Emerging Therapies, Case Reports, Patient Journey
August 05, 2021 07:28 ET
|
Research and Markets
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML)- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. The...
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
December 09, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
November 06, 2019 09:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results
August 13, 2019 16:05 ET
|
Cyclacel
- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or...
Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
July 22, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...